Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adenocarcinoma of the Gastroesophageal Junction: early-phase trial registry
A small indexed set (8 trials) with no open enrollment listed right now.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count
Adenocarcinoma of the Gastroesophageal Junction: 8 US clinical trials tracked, none currently recruiting.
Adenocarcinoma of the Gastroesophageal Junction is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition adenocarcinoma-of-the-gastroesophageal-junction
OPEN 0 | RECR 0% | LATE 0 | EARLY 8 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Adenocarcinoma of the Gastroesophageal Junction has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adenocarcinoma of the Gastroesophageal Junction on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adenocarcinoma of the Gastroesophageal Junction is recruiting below its size-band peers.
0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Adenocarcinoma of the Gastroesophageal Junction research.
National Cancer Institute (NCI) accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Adenocarcinoma of the Gastroesophageal Junction trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Adenocarcinoma of the Gastroesophageal Junction research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Induction FLOT With CROSS CRT for Esophageal Cancer
University of Colorado, Denver
NCT04028167
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
NCT01333033
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Leap Therapeutics
NCT02013154
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
NCT00982592
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Roswell Park Cancer Institute
NCT01178944
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
NCT00607594
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
NCT01612546
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Wake Forest University Health Sciences
NCT01561014
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Adenocarcinoma of the Gastroesophageal Junction records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adenocarcinoma of the Gastroesophageal Junction trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adenocarcinoma of the Gastroesophageal Junction page
8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Adenocarcinoma of the Gastroesophageal Junction trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Adenocarcinoma of the Gastroesophageal Junction trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenocarcinoma of the Gastroesophageal Junction condition card totals 8 registered trials; most-linked intervention fluorouracil; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.